// App-Quantinova.ai

: Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study

Researchers

Presenter

  • A. David Burden

Principal Investigators

  • Yukari Okubo

  • Min Zheng

  • Diamant Thaçi

  • Peter van de Kerkhof

  • Mogana Sivalingam

  • Christian Thoma

  • Siew Eng Choon

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Department of Breast Surgical Oncology,Tokyo Medical University, Tokyo, Japan

  • Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China

  • University of Lubeck, Lubeck, Germany

  • Department of Dermatology, Radboud University, Nijmegen, the Netherlands

  • Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Boehringer Ingelheim International GmbH, Biberach, Germany

  • Department of Dermatology, Hospital Sultanah Aminah, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia

Locations

  • China

  • Germany

  • United Kingdom

  • Japan

  • Malaysia

  • United States

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Infectious Diseases (ID)

  • Genetic Disorder

  • Dermatology

Disease

  • Psoriasis 14, pustular

  • Systemic inflammation

  • Psoriasis

Biomarkers

  • Interleukin-36

Drug/Treatment

  • Interleukin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • N/A

Study Id's

  • NCT03782792

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved